Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PHI-501 |
Synonyms | |
Therapy Description |
PHI-501 is a pan-RAF inhibitor, which potentially reduces tumor cell migration and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 1627). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PHI-501 | PHI501|PHI 501 | RAF Inhibitor (Pan) 28 | PHI-501 is a pan-RAF inhibitor, which potentially reduces tumor cell migration and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 1627). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61R | melanoma | predicted - sensitive | PHI-501 | Preclinical - Cell culture | Actionable | In a preclinical study, PHI-501 inhibited growth and migration and induced apoptosis in a melanoma cell line harboring NRAS Q61R in culture (Cancer Res (2023) 83 (7_Supplement): 1627). | detail... |
BRAF G464E | melanoma | predicted - sensitive | PHI-501 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PHI-501 inhibited growth and migration and induced apoptosis in a melanoma cell line harboring BRAF G464E in culture and inhibited tumor growth in a cell line xenograft model (Cancer Res (2023) 83 (7_Supplement): 1627). | detail... |
BRAF V600E | melanoma | predicted - sensitive | PHI-501 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PHI-501 inhibited growth and migration and induced apoptosis in a melanoma cell line harboring BRAF V600E and induced dose-dependent tumor growth inhibition in a cell line xenograft model (Cancer Res (2023) 83 (7_Supplement): 1627). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|